Five Prime Therapeutics, Inc. (FPRX) Director Sells $72,468.00 in Stock
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Director William R. Ringo sold 1,800 shares of Five Prime Therapeutics stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $40.26, for a total value of $72,468.00. Following the sale, the director now directly owns 1,200 shares in the company, valued at $48,312. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Five Prime Therapeutics, Inc. (NASDAQ FPRX) traded down 5.21% during mid-day trading on Tuesday, reaching $38.19. 335,684 shares of the company’s stock traded hands. The stock’s market cap is $1.07 billion. The firm has a 50 day moving average price of $33.83 and a 200-day moving average price of $31.79. Five Prime Therapeutics, Inc. has a 12 month low of $25.97 and a 12 month high of $60.98.
Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($1.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.15) by ($0.43). Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The company had revenue of $7.80 million for the quarter, compared to the consensus estimate of $8.32 million. During the same quarter last year, the business earned ($0.49) EPS. Five Prime Therapeutics’s revenue was down 16.1% on a year-over-year basis. On average, analysts predict that Five Prime Therapeutics, Inc. will post ($5.29) earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in FPRX. Rockefeller Financial Services Inc. bought a new position in shares of Five Prime Therapeutics in the second quarter worth $210,000. Alliancebernstein L.P. lifted its position in Five Prime Therapeutics by 9.2% during the first quarter. Alliancebernstein L.P. now owns 97,770 shares of the biotechnology company’s stock worth $3,534,000 after purchasing an additional 8,220 shares during the period. Goldman Sachs Group Inc. lifted its position in Five Prime Therapeutics by 142.2% during the first quarter. Goldman Sachs Group Inc. now owns 217,462 shares of the biotechnology company’s stock worth $7,861,000 after purchasing an additional 127,693 shares during the period. Marshall Wace North America L.P. lifted its position in Five Prime Therapeutics by 19.6% during the second quarter. Marshall Wace North America L.P. now owns 341,387 shares of the biotechnology company’s stock worth $10,241,000 after purchasing an additional 56,058 shares during the period. Finally, AXA lifted its position in Five Prime Therapeutics by 77.0% during the first quarter. AXA now owns 15,400 shares of the biotechnology company’s stock worth $557,000 after purchasing an additional 6,700 shares during the period. 84.05% of the stock is currently owned by institutional investors.
FPRX has been the subject of a number of recent research reports. Jefferies Group LLC reissued a “buy” rating and issued a $52.00 target price on shares of Five Prime Therapeutics in a report on Tuesday, September 12th. BMO Capital Markets restated a “hold” rating and set a $39.00 target price on shares of Five Prime Therapeutics in a research report on Friday, September 22nd. Royal Bank Of Canada began coverage on Five Prime Therapeutics in a research note on Thursday, September 14th. They issued an “outperform” rating and a $41.00 price target on the stock. ValuEngine raised Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Finally, BidaskClub cut Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $54.86.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.